VCEL: Vericel Corp. Company Value to Net Income

Corporate emblem and logo of Vericel Corp. (VCEL)

Vericel Corporation (VCEL) is implementing ESG standards in biomanufacturing, strictly adhering to ethics and energy efficiency. The company is advancing cutting-edge regenerative medicine by creating tissues from patient cells for injury therapy. The company's fundamental P/E demonstrates the link between market capitalization and actual earnings, while the 89.00 level indicates the status of the parameter. A stable cash flow is ensured by the uniqueness of its cellular products for cartilage repair.

Vericel Corporation (VCEL) Price to Earnings Ratio: for the period 07/04/2022 - 11/14/2026

Analytical breakdowns for Vericel Corporation

- price and consensus price forecast:
Stock Price vcel.com|VCEL - Consensus Target
- market capitalization information:
Market Value Vericel Corporation|VCEL - Total Company Value
- balance sheet net asset value indicators:
Net Assets per Share Vericel|VCEL - Company Book Value|Market Capitalization to Book Value Ratio vcel.com|VCEL - Company Total Assets
- company liabilities and liquidity data:
Total Debt to Capital Coefficient Vericel Corporation|VCEL - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Vericel Inc.|VCEL - Company Total Debt|Debt to Book Capitalization Ratio Vericel Corporation|VCEL - Company Long-Term Debts|Short-Term Debt Vericel|Intermediate Coverage Ratio vcel.com
- earnings and market multiples details:
VCEL - Net Profit|Company Profit Forecast Vericel Corporation|VCEL - P/E Multiple|Projected Price to Earnings Vericel Corp|VCEL - PEG Multiple|Company Value to EBITDA Vericel Corporation|VCEL - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Vericel|VCEL - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months vcel.com|VCEL - Earnings growth in current year|Expected earnings per share growth for next year Vericel Corporation
- sales volume and revenue indicators:
VCEL - Company Revenue|Company Expected Sales Volume vcel.com|VCEL - Price-to-Revenue Ratio|Forward Price to Sales Vericel Corporation
General company analysis:vcel.com
Manufactured product of vcel.com

Scaling cell implant sales amid high fixed costs creates operating leverage, which is reflected in the current market P/E dynamics of Vericel Corporation (VCEL). This ratio compares market capitalization to net income, allowing investors to assess the cost of one dollar of earnings and determine whether the asset is overvalued or undervalued relative to the business growth rate.

Key competitors

P/E Multiple krystalbio.com|Price to Earnings Ratio APGE (Apogee Therapeutics, Inc.)|ARQT (Arcutis) - Company Value to Net Income|Price to Earnings Ratio Oruka Corp ORKA|Business Payback Period Sanara MedTech, Inc. (SMTI)|DBVT - Price to Earnings Ratio|SLSN - P/E Multiple|DERM: P/E Multiple|FBRX - Business Payback Period|Price to Earnings Ratio Empro|Price to Earnings Multiple SLGL (Sol-Gel Technologies, Ltd.)|Price to Earnings Ratio AXIL (AXIL Brands, Inc.)|Price to Earnings Ratio MDCX (medicuspharma.com)|P/E Multiple VRCA (Verrica Pharmaceuticals Inc.)|Hoth Therapeutics Inc. (HOTH) - Market Cap to Earnings|BFRI - Price to Earnings Ratio|Company Value to Net Income VYNE (VYNE Therapeutics)|SNOA: P/E Multiple|QNRX - Business Payback Period|AZTR (Azitra) - P/E Multiple|Price to Earnings Ratio Dermata Therapeutics Inc (DRMA)|P/E Multiple ELAB|RVNC - Market Cap to Earnings